TY - JOUR
T1 - Sleep-disordered breathing and left ventricular scar on cardiac magnetic resonance
T2 - Results of the multi-ethnic study of atherosclerosis
AU - Shah, Neomi A.
AU - Reid, Michelle
AU - Kizer, Jorge R.
AU - Sharma, Ravi K.
AU - Shah, Ravi V.
AU - Kundel, Vaishnavi
AU - Ambale-Venkatesh, Bharath
AU - Fayad, Zahi A.
AU - Shea, Steven J.
AU - Kaplan, Robert C.
AU - Lima, Joao A.C.
AU - Redline, Susan
N1 - Funding Information:
All authors have seen and approved the manuscript. Work for this study was performed at Icahn School of Medicine at Mount Sinai. This study was funded by contracts with University of Washington Coordinating Center (HHSN268201500003I, N01-HC-95159), UniversityofCalifornia,Los AngelesField Center (N01-HC-95160), Columbia UniversityField Center (N01-HC-95161), Johns Hopkins University Field Center (N01-HC-95162), University of Minnesota Field Center (N01-HC-95163), Northwestern University Field Center (N01-HC-95164), Wake Forest University Field Center (N01-HC-95165),Central Laboratory (N01-HC-95166), Ultrasound Reading Center (N01-HC-95167), MRI Reading Center (N01-HC-95168) and CT Reading Center (N01-HC-95169) from the National Heart, Lung, and Blood Institute, andbygrantsUL1-TR-000040(Columbia ClinicalandTranslationalScienceAwards[CTSA]), UL1-TR-001079 (Johns Hopkins Institute for Clinical and Translational Research [ICTR]), and UL1-TR-001420 (Wake Forest University Clinical and Translational Science Awards [CTSA]) from National Center for Advancing Translational Sciences (NCATS). The MESA Sleep study was support by National Heart, Lung, and Blood Institute Grant HL56984. Dr. Susan Redline was partially supported by Grant R35 HL135818. Dr. Neomi A Shah has funding from the National Institute of Health/National Heart, Lung, and Blood Institute (Grants 5K23HL125923-03, 1R03HL140273-01, 1R01HL143221-01). Jorge Kizer reports stock ownership in AmGen, Gilead Sciences, Johnson & Johnson, and Pfizer. All other authors report no conflict of interest.
Funding Information:
All authors have seen and approved the manuscript. Work for this study was performed at Icahn School of Medicine at Mount Sinai. This study was funded by contracts with University of Washington Coordinating Center (HHSN268201500003I, N01-HC-95159), University of California, Los Angeles Field Center (N01-HC-95160), Columbia University Field Center (N01-HC-95161), Johns Hopkins University Field Center (N01-HC-95162), University of Minnesota Field Center (N01-HC-95163), Northwestern University Field Center (N01-HC-95164), Wake Forest University Field Center (N01-HC-95165),Central Laboratory (N01-HC-95166), Ultrasound Reading Center (N01-HC-95167), MRI Reading Center (N01-HC-95168) and CT Reading Center (N01-HC-95169) from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040 (Columbia Clinical and Translational Science Awards [CTSA]), UL1-TR-001079 (Johns Hopkins Institute for Clinical and Translational Research [ICTR]), and UL1-TR-001420 (Wake Forest University Clinical and Translational Science Awards [CTSA]) from National Center for Advancing Translational Sciences (NCATS). The MESA Sleep study was support by National Heart, Lung, and Blood Institute Grant HL56984. Dr. Susan Redline was partially supported by Grant R35 HL135818. Dr. Neomi A Shah has funding from the National Institute of Health/National Heart, Lung, and Blood Institute (Grants 5K23HL125923-03, 1R03HL140273-01, 1R01HL143221-01). Jorge Kizer reports stock ownership in AmGen, Gilead Sciences, Johnson & Johnson, and Pfizer. All other authors report no conflict of interest.
Publisher Copyright:
Copyright © 2020 American Academy of Sleep Medicine. All rights reserved.
PY - 2020/6/15
Y1 - 2020/6/15
N2 - Study Objectives: The objectives of this study were to evaluate the independent association between sleep-disordered breathing (SDB) using overnight polysomnography and left ventricular (LV) scar using cardiac magnetic resonance (CMR) with late-gadolinium enhancement in a community-based cohort of the Multi-Ethnic Study of Atherosclerosis. Methods: Our analytical sample includes 934 participants from the fifth examination of the Multiethnic Study of Atherosclerosis who underwent both polysomnography and CMR. SDB was categorized as follows: no-SDB (apnea-hypopnea index [AHI] < 5 events/h), mild SDB (5 events/h ≤ AHI < 15 events/h), and moderate-severe SDB (AHI ≥ 15 events/h). LV scar was considered present if there was presence of scar on CMR (late-gadolinium enhancement > 0%). Logistic regression with multivariable adjustment for confounders (age, sex, race/ethnicity, body mass index, and cardiometabolic risk factors) was used to examine the independent association of SDB with LV scar. Confounders were identified using directed acyclic graphs. Results: The mean age of our sample was 67.0 ± 8.5 years (SD), with 49% (n = 461) females and a prevalence of SDB (AHI ≥ 5 events/h) of 63% (n = 590). LV scar was more prevalent in individuals with SDB (9.5%) versus those without SDB (3.8%; P <.01), and 88% of all LV scars were clinically unrecognized. After multivariable adjustment, both mild SDB and moderate-severe SDB were independently associated with LV scar (odds ratio, 2.53; 95% confidence interval, 1.13-5.64 and odds ratio, 2.31; 95% confidence interval, 1.01-5.24, respectively). Conclusions: In a community-based cohort, SDB (including mild) is independently associated with a more than 2-fold increase in the odds of LV scar presence measured using CMR with late-gadolinium enhancement. Most LV scars were clinically unrecognized. The impact of SDB treatment on subclinical myocardial infarction needs to be investigated in future studies.
AB - Study Objectives: The objectives of this study were to evaluate the independent association between sleep-disordered breathing (SDB) using overnight polysomnography and left ventricular (LV) scar using cardiac magnetic resonance (CMR) with late-gadolinium enhancement in a community-based cohort of the Multi-Ethnic Study of Atherosclerosis. Methods: Our analytical sample includes 934 participants from the fifth examination of the Multiethnic Study of Atherosclerosis who underwent both polysomnography and CMR. SDB was categorized as follows: no-SDB (apnea-hypopnea index [AHI] < 5 events/h), mild SDB (5 events/h ≤ AHI < 15 events/h), and moderate-severe SDB (AHI ≥ 15 events/h). LV scar was considered present if there was presence of scar on CMR (late-gadolinium enhancement > 0%). Logistic regression with multivariable adjustment for confounders (age, sex, race/ethnicity, body mass index, and cardiometabolic risk factors) was used to examine the independent association of SDB with LV scar. Confounders were identified using directed acyclic graphs. Results: The mean age of our sample was 67.0 ± 8.5 years (SD), with 49% (n = 461) females and a prevalence of SDB (AHI ≥ 5 events/h) of 63% (n = 590). LV scar was more prevalent in individuals with SDB (9.5%) versus those without SDB (3.8%; P <.01), and 88% of all LV scars were clinically unrecognized. After multivariable adjustment, both mild SDB and moderate-severe SDB were independently associated with LV scar (odds ratio, 2.53; 95% confidence interval, 1.13-5.64 and odds ratio, 2.31; 95% confidence interval, 1.01-5.24, respectively). Conclusions: In a community-based cohort, SDB (including mild) is independently associated with a more than 2-fold increase in the odds of LV scar presence measured using CMR with late-gadolinium enhancement. Most LV scars were clinically unrecognized. The impact of SDB treatment on subclinical myocardial infarction needs to be investigated in future studies.
KW - Cardiac magnetic resonance
KW - Late-gadolinium enhancement
KW - Left ventricular scar
KW - Myocardial injury
KW - Obstructive sleep apnea
KW - Sleep apnea
KW - Sleep-disordered breathing
UR - http://www.scopus.com/inward/record.url?scp=85086682728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086682728&partnerID=8YFLogxK
U2 - 10.5664/jcsm.8340
DO - 10.5664/jcsm.8340
M3 - Article
C2 - 32029066
AN - SCOPUS:85086682728
SN - 1550-9389
VL - 16
SP - 855
EP - 862
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 6
ER -